Biomarkers, such as programmed death receptor-ligand 1 (PD-L1), tumor mutational burden, and gene signatures demonstrating an inflamed tumor microenvironment are being evaluated to predict response to immunotherapy; however, it is clear that some patients who express a positive predictive biomarker will not respond to treatment and some who lack that biomarker will respond. This evidence concerns the gene CD274 and neoplasm.